ERBB2 and breast cancer: Compared to hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, TNBC presents a greater risk of distant recurrence within 3–5 years of diagnosis and has worse 5-year survival outcomes2–4.